{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.5","upperLimit":"59.2","value":"41.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\\<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits.","dispersionType":"95% Confidence Interval","groups":[{"description":"Encorafenib + binimetinib + cetuximab. Encorafenib: Orally, once daily. Binimetinib: Orally, twice daily. Cetuximab: Standard of care.","id":"OG000","title":"Combined Safety Lead-in"}],"paramType":"NUMBER","populationDescription":"The SLI Efficacy Set consisted of all CSLI participants in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).","reportingStatus":"POSTED","timeFrame":"From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)","title":"(Safety Lead-in) Objective Response Rate (ORR) by BICR","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}